U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21NO4.ClH
Molecular Weight 351.8252
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYCODONE HYDROCHLORIDE

SMILES

CN1CC[C@@]23c4c5ccc(c4O[C@@]3([H])C(=O)CC[C@]2([C@@]1([H])C5)O)OC.Cl

InChI

InChIKey=MUZQPDBAOYKNLO-RKXJKUSZSA-N
InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C18H21NO4
Molecular Weight 315.3643
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html

Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-622425600000
Primary
PERCODAN-DEMI

Approved Use

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.)

Launch Date

-622425600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
22.2 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
39.3 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
15.7 ng/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 ng/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
128.2 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
133 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
268.2 ng × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.3 ng × h/mL
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
99 ng × h/mL
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.9 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
3.55 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.85 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
55%
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
55%
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
5 mg 4 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55%
3.33 mg 6 times / day steady-state, oral
dose: 3.33 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
OXYCODONE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
healthy, 30 years
Health Status: healthy
Age Group: 30 years
Sex: M
Sources:
Other AEs: Pulmonary edema...
Other AEs:
Pulmonary edema
Sources:
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 1.7%)
Dizziness (grade 1-2, 1.7%)
Abdominal pain (grade 1-2, 0.8%)
Sources:
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Headache, Vomiting...
AEs leading to
discontinuation/dose reduction:
Headache (grade 1-2, 0.8%)
Vomiting (grade 1-2, 0.8%)
Nausea (grade 1-2, 0.8%)
Somnolence (grade 1-2, 0.8%)
Sources:
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (grade 1-2, 6.3%)
Dizziness (grade 1-2, 4.8%)
Confusion (grade 1-2, 3.2%)
Sources:
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Vomiting, Flu syndrome...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 1-2, 0.8%)
Flu syndrome (grade 1-2, 0.8%)
Confusion (grade 1-2, 0.8%)
Fatigue (grade 1-2, 0.8%)
Sources:
6 mg 2 times / day single, oral
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
Disc. AE: Vomiting...
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources:
healthy, mean age 36 years
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (2.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Pulmonary edema
30 mg 1 times / day single, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: single
Dose: 30 mg, 1 times / day
Sources:
healthy, 30 years
Health Status: healthy
Age Group: 30 years
Sex: M
Sources:
Abdominal pain grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Dizziness grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea grade 1-2, 1.7%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Headache grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Somnolence grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Vomiting grade 1-2, 0.8%
Disc. AE
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Confusion grade 1-2, 3.2%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Dizziness grade 1-2, 4.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea grade 1-2, 6.3%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Confusion grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Fatigue grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Flu syndrome grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Vomiting grade 1-2, 0.8%
Disc. AE
5 mg 4 times / day multiple, oral
Recommended
Dose: 5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 5 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Vomiting 11.4%
Disc. AE
6 mg 2 times / day single, oral
Studied dose
Dose: 6 mg, 2 times / day
Route: oral
Route: single
Dose: 6 mg, 2 times / day
Sources:
healthy, mean age 33 years
Vomiting 2.5%
Disc. AE
15 mg 1 times / day single, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: single
Dose: 15 mg, 1 times / day
Sources:
healthy, mean age 36 years
Health Status: healthy
Age Group: mean age 36 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
yes
yes
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Page: 7
yes
yes (co-administration study)
Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001).
Tox targets
PubMed

PubMed

TitleDatePubMed
Advancement of opioid analgesia with controlled-release oxycodone.
2001
Opioid formulations: tailoring to the needs in chronic pain.
2001
Strategies for the treatment of cancer pain in the new millennium.
2001
"No, Duke. No divorce".
2001 Aug 20
Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital.
2001 Dec
On the frontlines of old battles.
2001 Jul
Identification of ozone-oxidation products of oxycodone by electrospray ion trap mass spectrometry.
2001 Jul
Profits vs. pain relief.
2001 Jul 2
Addressing OxyContin abuse.
2001 Jul-Aug
Prescription for addiction?
2001 Mar
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration.
2001 Mar
Painkiller crackdown.
2001 May 14
Drug dependence studies and regulations: an overview of the past and present.
2001 Nov
The use of oxycodone in cancer-related pain: a literature review.
2001 Nov
Clinical case study.
2001 Nov-Dec
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Opioid therapy for chronic painful conditions.
2001 Oct
States respond to growing abuse of painkiller.
2001 Oct-Nov
Controlled-release oxycodone hydrochloride (OxyContin).
2001 Sep
Managing postoperative pain.
2001 Sep
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine.
2001 Sep
Oxycodone/ibuprofen.
2002
Hydromorphone for acute and chronic pain.
2002
The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid.
2002 Apr
Capillary electrophoresis and capillary electrophoresis-ion trap multiple-stage mass spectrometry for the differentiation and identification of oxycodone and its major metabolites in human urine.
2002 Apr 25
Severe chronic renal failure in association with oxycodone addiction: a new form of fibrillary glomerulopathy.
2002 Aug
Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children.
2002 Feb
Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.
2002 Feb
Treatment of painful sickle cell leg ulcers with topical opioids.
2002 Feb 1
A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma.
2002 Jan
Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain.
2002 Jan
Recovery after tonsillectomy in adults: a three-week follow-up study.
2002 Jan
A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care.
2002 Jan-Feb
Safety and efficacy of controlled-release oxycodone: a systematic literature review.
2002 Jul
OxyContin and neonatal abstinence syndrome.
2002 Jun
There is no accounting for accountability.
2002 Mar
Validity and reliability of three commercially available breath-by-breath respiratory systems.
2002 Mar
[Chronic pain of the musculoskeletal system. Make your patients move!].
2002 Mar 14
OxyContin Use and Abuse.
2002 Mar-Apr
From physician to inmate.
2002 May
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery.
2002 May
Venous malformations associated with central pain: report of a case.
2002 Nov
Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes.
2002 Nov
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases.
2002 Oct
Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.
2002 Oct
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy.
2002 Oct
Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery.
2002 Oct
Oxycontin--misuse and abuse.
2002 Summer
Patents

Sample Use Guides

For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration: Oral
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:46 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:46 UTC 2021
Record UNII
C1ENJ2TE6C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYCODONE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
OXYCODONE HYDROCHLORIDE [USAN]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF XARTEMIS
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF OXYCET
Common Name English
ROXIPRIN COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE [MI]
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYL-, HYDROCHLORIDE, (5.ALPHA.)-
Systematic Name English
OXYCODONE HYDROCHLORIDE CII [USP-RS]
Common Name English
OXYCODONE HYDROCHLORIDE [MART.]
Common Name English
COMBUNOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TARGINIQ
Brand Name English
4,5.ALPHA.-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE HYDROCHLORIDE
Systematic Name English
OXYCET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
ANHYDROUS OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXILOX
Common Name English
TROXYCA COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXIPRIN
Common Name English
OXYCODONE HYDROCHLORIDE [WHO-DD]
Common Name English
OXYCODONE HYDROCHLORIDE [VANDF]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TYLOX
Common Name English
TARGINIQ COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
OXECTA
Brand Name English
OXYCODONE HCL
Common Name English
CODOXY COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCODAN-DEMI
Common Name English
PERCODAN-DEMI COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF COMBUNOX
Common Name English
PERCODAN COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
XARTEMIS COMPONENT OXYCODONE HYDROCHLORIDE
Brand Name English
ROXICET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCONTIN
Brand Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF ROXICET
Common Name English
ROXICODONE
Brand Name English
PERCOCET COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF CODOXY
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF TROXYCA
Brand Name English
ROXYBOND
Brand Name English
ENDOCODONE
Brand Name English
TYLOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
ROXILOX COMPONENT OXYCODONE HYDROCHLORIDE
Common Name English
OXYCODONE HYDROCHLORIDE CII
USP-RS  
Common Name English
OXYCODONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
OXYCODONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
OXYCODONE HYDROCHLORIDE COMPONENT OF PERCOCET
Common Name English
Classification Tree Code System Code
DEA NO. 9143
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
NCI_THESAURUS C67413
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
NCI_THESAURUS C1506
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
Code System Code Type Description
USP_CATALOG
1485205
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C48010
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
CAS
124-90-3
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
FDA UNII
C1ENJ2TE6C
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
PUBCHEM
5462350
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
RXCUI
82063
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY RxNorm
EVMPD
SUB03583MIG
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
ECHA (EC/EINECS)
204-717-1
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
MERCK INDEX
M8328
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL656
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
DRUG BANK
DBSALT000277
Created by admin on Fri Jun 25 20:55:46 UTC 2021 , Edited by admin on Fri Jun 25 20:55:46 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of impurities D and E: not more than 10 times the area of the peak due to oxycodone in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
sum of impurities D and E: not more than 10 times the area of the peak due to oxycodone in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY